|
|
|
|
| LEADER |
01813nam a2200313 u 4500 |
| 001 |
EB001839368 |
| 003 |
EBX01000000000000001003357 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 100 |
1 |
|
|a Assasi, Nazila
|
| 245 |
0 |
0 |
|a Icatibant for patients with type III hereditary angioedema
|h Elektronische Ressource
|b an updated review of clinical effectiveness and harms
|c Nazila Assasi, Andrea Ryce
|
| 250 |
|
|
|a Version 1.0
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c March 09, 2017, 2017
|
| 300 |
|
|
|a 1 PDF file (20 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Bradykinin B2 Receptor Antagonists / therapeutic use
|
| 653 |
|
|
|a Bradykinin B2 Receptor Antagonists / adverse effects
|
| 653 |
|
|
|a Hereditary Angioedema Type III / drug therapy
|
| 700 |
1 |
|
|a Ryce, Andrea
|e [author]
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 740 |
0 |
2 |
|a Icatibant for patients with type III hereditary angioedema
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a Supplement to: Icatibant for patients with type III hereditary angioedema. February 6, 2014
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK470514
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The purpose of this report is to review the clinical effectiveness and safety of icatibant when it is used in patients with Type III HAE. This report is an update of a previous CADTH Rapid Response report (2014),15 which found inconclusive evidence from two observational studies to support the use of icatibant in Type III HAE patients
|